Rituxumab: Clinical Trials

1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	2	Active not recruiting 1, Recruiting 1
Phase 1	1	Completed 1
Phase 2	1	Completed 1

Follow Rituxumab: new trials by email Literature Review of Rituxumab trials Research Report on Rituxumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Sinocelltech Ltd.	101	2026-06-04	2026-08-13
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Rituxumab - Diffuse Large B-cell Lymphoma	Phase 3	Active not recruiting	Hoffmann-La Roche	270	2021-02-23	2026-10-02
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Polatuzumab Vedotin, Rituxumab - B-cell Non-Hodgkin Lymphoma	Phase 1 / Phase 2	Completed	Hoffmann-La Roche	117	2019-03-08	2024-12-18

Conditions studied

Dendritic Cell Sarcoma, Interdigitating (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)

Sponsors

Hoffmann-La Roche (2)  ·  Sinocelltech Ltd. (1)

Countries

China (2)  ·  France (2)  ·  Poland (2)  ·  South Korea (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Denmark (1)  ·  Germany (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 37581593, PMID 39550172, PMID 39908481, PMID 40749164, PMID 42269085

NIH funding

2018 (1)